Amphastar Pharmaceuticals to Release First Quarter Earnings and Hold Conference Call on May 7th, 2025
Amphastar Pharmaceuticals has scheduled its Q1 2025 earnings release and conference call for May 7th, 2025. The company will disclose financial results after market close, followed by a conference call at 2:00 p.m. Pacific Time.
Amphastar, a bio-pharmaceutical company, specializes in developing and manufacturing complex injectable, inhalation, and intranasal products. Their product portfolio includes technically challenging generic and proprietary medications, primarily used in hospitals and urgent care settings. The company also produces insulin API products and distributes through group purchasing organizations and drug wholesalers.
Investors can join the conference call via toll-free number 877-407-0989 or international number 201-389-0921. A webcast will be available on the company's website, with a replay accessible within 24 hours after the live call.
Amphastar Pharmaceuticals ha programmato la pubblicazione dei risultati finanziari del primo trimestre 2025 e la conferenza telefonica per il 7 maggio 2025. L'azienda comunicherà i dati economici dopo la chiusura del mercato, seguiti da una conference call alle 14:00 ora del Pacifico.
Amphastar, azienda biofarmaceutica, si specializza nello sviluppo e nella produzione di prodotti iniettabili complessi, per inalazione e intranasali. Il loro portafoglio comprende farmaci generici e proprietari tecnicamente impegnativi, principalmente utilizzati in ospedali e strutture di pronto soccorso. L'azienda produce anche principi attivi per insulina e distribuisce tramite organizzazioni di acquisto di gruppo e grossisti farmaceutici.
Gli investitori possono partecipare alla conference call chiamando il numero verde 877-407-0989 o il numero internazionale 201-389-0921. Una trasmissione web sarà disponibile sul sito aziendale, con la possibilità di riascolto entro 24 ore dalla diretta.
Amphastar Pharmaceuticals ha programado la publicación de sus resultados del primer trimestre de 2025 y la conferencia telefónica para el 7 de mayo de 2025. La empresa dará a conocer los resultados financieros después del cierre del mercado, seguida de una llamada a las 2:00 p.m. hora del Pacífico.
Amphastar, una compañía biofarmacéutica, se especializa en el desarrollo y fabricación de productos inyectables complejos, para inhalación e intranasales. Su portafolio incluye medicamentos genéricos y patentados técnicamente desafiantes, usados principalmente en hospitales y centros de atención urgente. También produce ingredientes farmacéuticos activos de insulina y distribuye a través de organizaciones de compra grupal y mayoristas de medicamentos.
Los inversionistas pueden unirse a la llamada a través del número gratuito 877-407-0989 o el número internacional 201-389-0921. Habrá una transmisión web disponible en el sitio web de la compañía, con una repetición accesible dentro de las 24 horas posteriores a la llamada en vivo.
Amphastar Pharmaceuticals는 2025년 1분기 실적 발표 및 컨퍼런스 콜을 2025년 5월 7일로 예정했습니다. 회사는 시장 마감 후 재무 결과를 공개하며, 이어서 태평양 시간 오후 2시에 컨퍼런스 콜을 진행할 예정입니다.
Amphastar는 복잡한 주사제, 흡입제 및 비강 내 제품을 개발 및 제조하는 바이오 제약 회사입니다. 이들의 제품 포트폴리오는 주로 병원과 응급 치료 환경에서 사용되는 기술적으로 까다로운 제네릭 및 독점 의약품을 포함합니다. 또한 인슐린 원료 의약품(API)을 생산하며 그룹 구매 조직과 의약품 도매상을 통해 유통합니다.
투자자들은 무료 전화번호 877-407-0989 또는 국제 전화번호 201-389-0921을 통해 컨퍼런스 콜에 참여할 수 있습니다. 회사 웹사이트에서 웹캐스트가 제공되며, 생중계 후 24시간 이내에 다시 듣기 서비스도 이용 가능합니다.
Amphastar Pharmaceuticals a programmé la publication de ses résultats du premier trimestre 2025 et la conférence téléphonique pour le 7 mai 2025. La société communiquera les résultats financiers après la clôture du marché, suivie d'une conférence téléphonique à 14h00, heure du Pacifique.
Amphastar, une entreprise biopharmaceutique, se spécialise dans le développement et la fabrication de produits injectables, inhalés et intranasaux complexes. Leur portefeuille comprend des médicaments génériques et propriétaires techniquement exigeants, principalement utilisés dans les hôpitaux et les services d'urgence. La société produit également des principes actifs d'insuline et distribue via des organisations d'achat groupé et des grossistes en médicaments.
Les investisseurs peuvent rejoindre la conférence téléphonique en appelant le numéro gratuit 877-407-0989 ou le numéro international 201-389-0921. Un webinaire sera disponible sur le site internet de la société, avec une rediffusion accessible dans les 24 heures suivant l'appel en direct.
Amphastar Pharmaceuticals hat die Veröffentlichung der Ergebnisse für das erste Quartal 2025 und die Telefonkonferenz für den 7. Mai 2025 geplant. Das Unternehmen wird die Finanzzahlen nach Börsenschluss bekannt geben, gefolgt von einer Telefonkonferenz um 14:00 Uhr Pazifischer Zeit.
Amphastar ist ein biopharmazeutisches Unternehmen, das sich auf die Entwicklung und Herstellung komplexer injizierbarer, inhalativer und intranasaler Produkte spezialisiert hat. Ihr Produktportfolio umfasst technisch anspruchsvolle generische und proprietäre Medikamente, die hauptsächlich in Krankenhäusern und Notfallkliniken eingesetzt werden. Das Unternehmen produziert außerdem Insulin-Wirkstoffprodukte und vertreibt diese über Einkaufsgemeinschaften und Arzneimittelgroßhändler.
Investoren können an der Telefonkonferenz über die gebührenfreie Nummer 877-407-0989 oder die internationale Nummer 201-389-0921 teilnehmen. Ein Webcast wird auf der Unternehmenswebsite verfügbar sein, mit einer Wiederholung innerhalb von 24 Stunden nach dem Live-Anruf.
- Company has a diverse product portfolio including generic and proprietary injectable, inhalation, and intranasal products
- BAQSIMI product shows potential for continued revenue growth
- Strong distribution network through group purchasing organizations and drug wholesalers
- Established presence in hospital and urgent care clinical settings
- None.
RANCHO CUCAMONGA, CA / ACCESS Newswire / April 30, 2025 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced that the Company will release results for its first quarter of 2025 ended March 31, 2025, after the market closes on Wednesday, May 7th, 2025, and will hold a conference call to discuss its financial results at 2:00 p.m. Pacific Time.
To access the conference call, dial toll free 877-407-0989, for international calls, dial 201-389-0921, ten minutes before the conference.
The call can also be accessed on the Investors page on the Company's website www.amphastar.com. The webcast replay of the call will be available on our Company website within 24 hours after the end of the live conference call.
Company Information
Amphastar is a bio-pharmaceutical company that focuses primarily on developing, manufacturing, marketing, and selling technically challenging generic and proprietary injectable, inhalation, and intranasal products. Additionally, the Company sells insulin API products. Most of the Company's finished products are used in hospital or urgent care clinical settings and are primarily contracted and distributed through group purchasing organizations and drug wholesalers. More information and resources are available at www.amphastar.com.
Forward Looking Statements
All statements in this press release and in the conference call referenced above that are not historical are forward-looking statements, including, among other things, statements relating to our expectations regarding future financial performance and business trends, our future growth, sales and marketing of our products, market size and expansion, product portfolio, product development, the timing of FDA filings or approvals, including the DMFs of ANP, the timing of product launches, acquisitions and other matters related to our pipeline of product candidates, the timing and results of clinical trials, the benefits BAQSIMI®, including its potential for continued revenue growth, the strategic trajectory of and market for our product pipeline, our ability to leverage our existing expertise and technology, and other future events. These statements are not facts but rather are based on Amphastar's historical performance and our current expectations, estimates, and projections regarding our business, operations, and other similar or related factors. Words such as "may," "might," "will," "could," "would," "should," "anticipate," "predict," "potential," "continue," "expect," "intend," "plan," "project," "believe," "estimate," and other similar or related expressions are used to identify these forward-looking statements, although not all forward-looking statements contain these words. You should not place undue reliance on forward-looking statements because they involve known and unknown risks, uncertainties, and assumptions that are difficult or impossible to predict and, in some cases, beyond Amphastar's control. Actual results may differ materially from those in the forward-looking statements as a result of a number of factors, including those described in Amphastar's filings with the Securities and Exchange Commission, including in our Annual Report on Form 10-K for the year ended December 31, 2024, filed with the SEC on March 3, 2025 and our other filings or reports that we may file with the SEC. In particular, there can be no guarantee that our sales strategies will be successful, or that we will continue to experience significant sales of BAQSIMI®. You can locate these reports through our website at http://ir.amphastar.com and on the SEC's website at www.sec.gov. The forward-looking statements in this release speak only as of the date of the release. Amphastar undertakes no obligation to revise or update information or any forward-looking statements in this press release or the conference call referenced above to reflect events or circumstances in the future, even if new information becomes available or if subsequent events cause our expectations to change.
Contact:
Bill Peters
Chief Financial Officer
(909) 476-3416
SOURCE: Amphastar Pharmaceuticals, Inc.
View the original press release on ACCESS Newswire
FAQ
When will Amphastar (AMPH) release Q1 2025 earnings?
How can investors join Amphastar's Q1 2025 earnings call?
What products does Amphastar Pharmaceuticals (AMPH) focus on?
Where are Amphastar (AMPH) products primarily used?
What is the potential growth outlook for Amphastar's BAQSIMI product?
